Tirzepatide's Skin Effects: Injection Reactions, Potential for Psoriasis Treatment, and Facial Aging Concerns

Tirzepatide causes injection-site reactions and rare skin adverse events, but its immunomodulatory properties show potential for treating inflammatory skin diseases like psoriasis and hidradenitis suppurativa.

El-Amawy, Heba Saed·Anais brasileiros de dermatologia·2026·
RPEP-151372026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Tirzepatide causes injection-site reactions comparable to semaglutide, rare severe dermatologic events, and facial volume loss from rapid weight loss, but shows immunomodulatory potential for inflammatory skin diseases.

Key Numbers

How They Did This

Narrative review of SURPASS clinical trials, case reports, pharmacovigilance data (PubMed, Scopus, Google Scholar through May 2025) focusing on dermatologic effects.

Why This Research Matters

As millions take tirzepatide, understanding its skin effects—both adverse and potentially therapeutic—helps dermatologists, prescribers, and patients make informed decisions.

The Bigger Picture

The skin effects of GLP-1/GIP drugs are an emerging area as use expands. The dual therapeutic/adverse skin profile mirrors the broader pattern of GLP-1 drug pleiotropic effects.

What This Study Doesn't Tell Us

Therapeutic skin benefits based on case reports only. Cosmetic effects are subjective. Pharmacovigilance data may underrepresent events.

Questions This Raises

  • ?Should dermatologists actively investigate tirzepatide for psoriasis in clinical trials?
  • ?Can cosmetic interventions (fillers) safely address tirzepatide-induced facial volume loss?
  • ?Do skin adverse events differ between branded and compounded tirzepatide?

Trust & Context

Key Stat:
Dual skin impact Tirzepatide causes skin adverse events but may also treat inflammatory skin diseases through immunomodulation
Evidence Grade:
Review of clinical trial safety data and case reports. Safety data well-established; therapeutic skin benefits are preliminary.
Study Age:
Published in 2025.
Original Title:
Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.
Published In:
Anais brasileiros de dermatologia, 101(1), 501255 (2026)
Database ID:
RPEP-15137

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Does tirzepatide cause skin problems?

Injection-site reactions are the most common skin effect. Rare cases of more serious skin reactions have been reported. The rapid weight loss can also cause facial volume loss and premature aging appearance.

Could tirzepatide treat skin conditions?

Early case reports suggest it may help psoriasis and hidradenitis suppurativa through its anti-inflammatory effects. However, clinical trials are needed to confirm these potential benefits.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-15137·https://rethinkpeptides.com/research/RPEP-15137

APA

El-Amawy, Heba Saed. (2026). Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.. Anais brasileiros de dermatologia, 101(1), 501255. https://doi.org/10.1016/j.abd.2025.501255

MLA

El-Amawy, Heba Saed. "Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications - A comprehensive review.." Anais brasileiros de dermatologia, 2026. https://doi.org/10.1016/j.abd.2025.501255

RethinkPeptides

RethinkPeptides Research Database. "Tirzepatide in dermatology: cutaneous adverse events, emergi..." RPEP-15137. Retrieved from https://rethinkpeptides.com/research/el-amawy-2026-tirzepatide-in-dermatology-cutaneous

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.